Barry Trachtenberg, MD
Advanced Heart Failure and Transplant Cardiology · Houston, TXNPI 1639331473
Payments from drug & device makers
Across 644 payments — averaging $546.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$166K
- Pfizer$86K
- AstraZeneca$70K
- Abbott$12K
- Bridgebio Pharma, Inc.$11K
- Akcea Therapeutics, Inc.$3K
- plus $3K from 27 others
What the payments were for
- Consulting fees$40,30813%
- Speaking & faculty fees$229,04375%
- Travel & lodging$20,2437%
- Food & beverage$16,4205%
- Education$1170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 189 | $166,429 |
| Pfizer(2 entities) | 98 | $85,934 |
| AstraZeneca(2 entities) | 82 | $70,463 |
| Abbott | 129 | $12,319 |
| Bridgebio Pharma, Inc. | 22 | $10,719 |
| Akcea Therapeutics, Inc. | 2 | $2,822 |
| Medtronic(2 entities) | 4 | $462 |
| E.r. Squibb & Sons, L.L.C. | 23 | $435 |
| Boston Scientific | 4 | $362 |
| Novartis | 13 | $294 |
| Amgen | 12 | $186 |
| Novo Nordisk | 3 | $172 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $157 |
| Scpharmaceuticals Inc. | 8 | $140 |
| Esperion Therapeutics, Inc. | 8 | $127 |
| Boehringer Ingelheim | 6 | $114 |
| Bayer | 5 | $113 |
| Edwards Lifesciences | 1 | $111 |
| Impulse Dynamics (USA) Inc. | 4 | $68 |
| Actelion Pharmaceuticals US, Inc. | 4 | $67 |
| Lexicon Pharmaceuticals, Inc. | 4 | $66 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $43 |
| Johnson & Johnson | 2 | $39 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $28 |
| Cardiva Medical, Inc. | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Tactile Systems Technology Inc | 1 | $22 |
| Astellas Pharma US Inc | 1 | $22 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Biosense Webster, Inc. | 1 | $16 |
| GE HealthCare | 1 | $15 |
| Haemonetics Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$77,195
- ONPATTRO$60,852
- WAINUA$59,410
- AMVUTTRA$51,228
- Attruby$10,422
- CardioMEMS HF System$5,855
- VYNDAMAX$3,092
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,903
- TEGSEDI$2,822
- CARDIOMEMS$1,255
- HeartWare HVAD$248
- WATCHMAN FLX$139
- HawkOne$125
- Watchman$113
- SAPIEN 3 Ultra RESILIA$111
How this compares
$351,872 in reported general payments places this provider in the 80th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 383 | $9,413,202 |
| WainuaEplontersen Sodium | 11 | $474,999 |
| EntrestoSacubitril/Valsartan | 355 | $467,463 |
| VyndaqelTafamidis Meglumine | 21 | $456,191 |
| EliquisApixaban | 271 | $295,077 |
| FarxigaDapagliflozin Propanediol | 228 | $207,775 |
| JardianceEmpagliflozin | 117 | $136,026 |
| Repatha SureclickEvolocumab | 47 | $44,627 |
| XareltoRivaroxaban | 19 | $25,896 |
| VeltassaPatiromer Calcium Sorbitex | 13 | $12,526 |
| Sirolimus | 20 | $11,005 |
| Metoprolol Succinate | 403 | $6,995 |
| Torsemide | 201 | $6,039 |
| Carvedilol | 440 | $4,615 |
| Spironolactone | 429 | $4,174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $85,934 | $10,164,470675 claims |
| AstraZenecaWainua, Farxiga | $70,463 | $682,774239 claims |
| NovartisEntresto | $294 | $467,463355 claims |
| Boehringer IngelheimJardiance | $114 | $136,026117 claims |
| Johnson & JohnsonXarelto | $39 | $25,89619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
Other advanced heart failure and transplant cardiology in Houston
- Ajith NairHouston$1.3M
- Ashrith GuhaHouston$525K
- Andrew CivitelloHouston$286K
- Arvind BhimarajHouston$269K
- Maria Patarroyo AponteHouston$166K
- Sriram NathanHouston$87K
- Rayan YousefzaiHouston$75K
- Cindy MartinHouston$67K
- Leo SimpsonHouston$30K
- Ju KimHouston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.